Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:MLTX NASDAQ:MTSR NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$11.48+1.8%$12.61$3.61▼$17.43$774.91M1.581.35 million shs217,914 shsMLTXMoonLake Immunotherapeutics$48.84+4.5%$42.85$31.42▼$58.26$3.13B1.27384,663 shs260,864 shsMTSRMetsera$32.20+6.9%$27.78$12.30▼$37.99$3.38BN/A903,760 shs204,354 shsVKTXViking Therapeutics$30.44+0.8%$27.50$18.92▼$81.73$3.40B0.624.04 million shs1.50 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-1.23%-4.33%-19.31%+61.14%+169.86%MLTXMoonLake Immunotherapeutics-1.58%+0.30%-0.28%+29.93%+7.42%MTSRMetsera+6.09%+12.05%+9.57%+97.25%+3,011,999,900.00%VKTXViking Therapeutics+9.74%+13.20%+8.48%+30.69%-40.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix2.7461 of 5 stars4.41.00.00.03.10.00.6MLTXMoonLake Immunotherapeutics1.9814 of 5 stars3.51.00.00.02.22.50.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/AVKTXViking Therapeutics3.8449 of 5 stars3.51.00.04.71.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.88Moderate Buy$17.1451.98% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$74.5059.36% UpsideMTSRMetsera 3.00Buy$55.0082.60% UpsideVKTXViking Therapeutics 3.00Buy$87.15188.68% UpsideCurrent Analyst Ratings BreakdownLatest CRMD, MLTX, MTSR, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CRMDCorMedixD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/30/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/25/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.006/24/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.006/23/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.006/20/2025CRMDCorMedixRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.006/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.006/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M17.60N/AN/A$1.40 per share8.06MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/AMTSRMetseraN/AN/AN/AN/A($2.46) per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.2251.2812.00N/A20.81%22.57%17.02%8/13/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/AVKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-14.41%-14.02%7/23/2025 (Estimated)Latest CRMD, MLTX, MTSR, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.73N/AN/AN/AN/AN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44N/AN/AN/AN/AN/A5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A4.213.99MLTXMoonLake Immunotherapeutics0.1821.1121.11MTSRMetseraN/A6.556.55VKTXViking TherapeuticsN/A44.2544.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%MLTXMoonLake Immunotherapeutics93.85%MTSRMetseraN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%MLTXMoonLake Immunotherapeutics12.05%MTSRMetseraN/AVKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3067.82 million64.23 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.30 millionOptionableMTSRMetsera81105.06 millionN/AN/AVKTXViking Therapeutics20112.31 million107.71 millionOptionableCRMD, MLTX, MTSR, and VKTX HeadlinesRecent News About These CompaniesFinancial Counselors Inc. Acquires 16,823 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)July 9 at 5:41 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 8.1% - Still a Buy?July 8 at 4:24 PM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Cambridge Investment Research Advisors Inc.July 8 at 3:24 AM | marketbeat.comBetter Growth Buy: Eli Lilly vs. Viking TherapeuticsJuly 7 at 3:45 AM | fool.comAugust 22nd Options Now Available For Viking Therapeutics (VKTX)July 5, 2025 | nasdaq.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of StockJuly 4, 2025 | insidertrades.comWhy I Think Viking Therapeutics Is an Asymmetric Growth OpportunityJuly 4, 2025 | fool.comViking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key FactsJuly 3, 2025 | zacks.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of StockJuly 3, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells $118,466.82 in StockJuly 3, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) CEO Sells 26,889 SharesJuly 3, 2025 | marketbeat.comVKTX - Viking Therapeutics Inc Sustainability - MorningstarJuly 3, 2025 | morningstar.comMH.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)July 2, 2025 | theglobeandmail.comViking Therapeutics (NASDAQ:VKTX) Shares Up 7.7% - Here's What HappenedJuly 2, 2025 | marketbeat.comIs Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?July 2, 2025 | zacks.comGot $200? 2 Biotech Stocks to Buy and Hold ForeverJuly 1, 2025 | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by BrokeragesJuly 1, 2025 | marketbeat.com3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking...June 29, 2025 | marketbeat.comViking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to NoteJune 27, 2025 | zacks.comWhy This Weight Loss Drug Company's Stock Surged TodayJune 26, 2025 | fool.comVKTX Initiates Phase 3 Study on Obesity Candidate VK2735June 26, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingCRMD, MLTX, MTSR, and VKTX Company DescriptionsCorMedix NASDAQ:CRMD$11.48 +0.20 (+1.76%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.MoonLake Immunotherapeutics NASDAQ:MLTX$48.84 +2.09 (+4.47%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Metsera NASDAQ:MTSR$32.20 +2.08 (+6.91%) As of 10:33 AM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Viking Therapeutics NASDAQ:VKTX$30.44 +0.25 (+0.84%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
